Receptor de Androgénio
O receptor de andrógenos (AR) é um receptor hormonal nuclear que é ativado pela ligação a andrógenos, como a testosterona e a diidrotestosterona. Este receptor desempenha um papel crucial no desenvolvimento e na manutenção das características masculinas, bem como na regulação de vários processos fisiológicos, incluindo o crescimento muscular, a libido e a densidade óssea. Inibidores do receptor de andrógenos são amplamente estudados no contexto do câncer de próstata, onde a sinalização do AR é frequentemente aumentada. Na CymitQuimica, oferecemos uma gama de moduladores do receptor de andrógenos de alta qualidade para apoiar sua pesquisa em endocrinologia, biologia do câncer e regulação hormonal.
Foram encontrados 207 produtos de "Receptor de Androgénio"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
RU 59063
CAS:<p>RU 59063 is a prototype of a new class of high-affinity nonsteroidal androgen receptor (AR) ligands.</p>Fórmula:C17H18F3N3O2SPureza:99.09%Cor e Forma:SolidPeso molecular:385.4YXG-158
CAS:<p>YXG-158 (Compound 23-h), an orally active androgen receptor (AR) degrader and cytochrome P450 17A1 (CYP17A1) inhibitor, exhibits AR degradation with a DC50 of 1</p>Fórmula:C30H36FN3OPureza:98%Cor e Forma:SolidPeso molecular:473.62Androgen receptor degrader-3
CAS:<p>Androgen Receptor Degrader-3 (ARD-3) is a compound that inhibits androgen receptor signaling and promotes the degradation of the receptor, with potential</p>Fórmula:C45H51ClN8O5Pureza:98%Cor e Forma:SolidPeso molecular:819.39EPI-7170
CAS:<p>EPI-7170: Ralaniten analogue, blocks androgen receptor, inhibits transcription in AR & variants, fights enzalutamide-resistant prostate cancer.</p>Fórmula:C22H28Cl3NO6SCor e Forma:SolidPeso molecular:540.88ID11916
CAS:<p>ID11916 is an orally active compound functioning as both an androgen receptor (AR) antagonist and a phosphodiesterase 5 (PDE5) inhibitor. It disrupts androgen binding to AR, impedes nuclear translocation, and blocks androgen-dependent transcriptional activity of AR, while simultaneously elevating intracellular cGMP levels by inhibiting PKG activation. Moreover, ID11916 exhibits potent anticancer effects in prostate cancer cell lines VCaP and 22Rv1, as well as in AR-positive breast cancer cell line SK-BR-3.</p>Fórmula:C29H27F3N8O3SCor e Forma:SolidPeso molecular:624.637Androstatrione
CAS:<p>Androstatrione is an androgenic compound.</p>Fórmula:C19H26O3Cor e Forma:SolidPeso molecular:302.41Androgen receptor antagonist 12
CAS:<p>Compound EF2 (Androgen receptor antagonist 12) is an orally active antagonist of the androgen receptor (AR) with an IC50 of 0.30 µM. It inhibits the transcriptional activity of mutant AR and the proliferation of AR-positive PCa (prostate cancer) cell lines. Additionally, Compound EF2 blocks the nuclear translocation of AR and suppresses tumor growth in the C4-2B xenograft mouse model. This compound is used for research in prostate cancer.</p>Fórmula:C12H8F3N3O2Cor e Forma:SolidPeso molecular:283.21SJ1008066
CAS:<p>SJ1008066 is a MAGE-A11 inhibitor with an IC50 of 0.13 μM. It binds to the MAGE homology domain (MHD) and disrupts the MAGE-A11:PCF11 interaction.</p>Fórmula:C21H22N4Cor e Forma:SolidPeso molecular:330.43Androgen receptor antagonist 11
CAS:<p>Androgen receptor antagonist 11 (compound N29) is a selective, orally available antagonist.</p>Fórmula:C20H19F3N4O3SCor e Forma:SolidPeso molecular:452.45AR/BET protein degrader-1
CAS:<p>AR/BET protein degrader-1 (Compound 149) is a dual-targeting protein degrader of Androgen Receptor and BET (bromodomain and extra-terminal domain), suitable for cancer research.</p>Fórmula:C43H44N6O5Peso molecular:724.85GLPG0492 (R enantiomer)
CAS:<p>GLPG0492 R enantiomer is the R enantiomer of GLPG-0492, a novel selective androgen receptor modulator.</p>Fórmula:C19H14F3N3O3Cor e Forma:SolidPeso molecular:389.33VNPP433-3β
CAS:<p>VNPP433-3β acts as a molecular glue degrader, targeting the androgen receptor (AR) and its splice variants (AR-Vs) as well as MAP kinase-interacting serine/threonine protein kinase Mnk1/2. It effectively inhibits the proliferation of cancer cells LNCaP, C4-2B, and CWR22Rv1, with GI50 values of 0.2, 0.3, and 0.31 μM, respectively. Additionally, VNPP433-3β shows favorable pharmacokinetics in CD-1 mice and suppresses tumor growth in the CWR22Rv1 xenograft mouse model.</p>Fórmula:C29H34N4Cor e Forma:SolidPeso molecular:438.61AR antagonist 4
<p>AR antagonist 4 (Compound 67-b) is an orally active androgen receptor (AR) antagonist that acts on wild-type AR (IC50: 246.6 nM).</p>Fórmula:C29H36N4OCor e Forma:SolidPeso molecular:456.62AR antagonist 10
CAS:<p>AR antagonist 10 (Compound Y5) is a potent, orally active androgen receptor (AR) antagonist with an IC50 value of 0.04 μM. It demonstrates a dual mechanism of action: antagonizing AR by disrupting AR dimerization and inducing AR degradation through the ubiquitin-proteasome pathway. This compound shows excellent activity against various resistant AR mutants and effectively inhibits the growth of LNCaP xenograft tumors. AR antagonist 10 is applicable for research in resistant prostate cancer.</p>Fórmula:C18H17ClN4O3SCor e Forma:SolidPeso molecular:404.871FL442
CAS:<p>FL442 is an Androgen Receptor (AR) modulator. This compound exhibits potent inhibitory effects in AR-dependent prostate cancer cells, showing similar suppression efficiency to the traditional antiandrogen drugs Bicalutamide and Enzalutamide. It also maintains antiandrogen activity against the Enzalutamide-resistant AR mutant F876L. The pharmacokinetic properties of FL442 in mice reveal a longer half-life (8 hours), excellent targeting (prostate tissue), and metabolic stability. Additionally, it is effective at inhibiting LNCaP tumor growth at low plasma concentrations (30 ng/mL).</p>Fórmula:C15H13F3N2OCor e Forma:SolidPeso molecular:294.27(+)-JJ-74-138
CAS:<p>(+)-JJ-74-138 is a novel non-competitive androgen receptor (AR) antagonist capable of inhibiting enzalutamide-resistant castration-resistant prostate cancer (CRPC).</p>Fórmula:C22H22F8N2OSCor e Forma:SolidPeso molecular:514.48LX1
CAS:<p>LX1, an anti-prostate cancer compound, specifically targets the androgen receptor (AR), AR variants, and the steroidogenic enzyme AKR1C3. It inhibits AKR1C3's enzymatic function, decreases the conversion of androstenedione to testosterone, and reduces the expression of both AR and AR-V7, subsequently downregulating their target genes. Additionally, LX1 is effective in overcoming tumor cell resistance to Enzalutamide, and when combined with Enzalutamide, it further suppresses tumor growth.</p>Fórmula:C22H15F6NO2Cor e Forma:SolidPeso molecular:439.35Androgen receptor degrader-5
CAS:<p>Androgen receptor degrader-5 (compound 14k) demonstrates superior capabilities, specifically in androgen receptor degradation and antiproliferative activity, showcasing its promising properties.</p>Fórmula:C29H25F4N5O2Cor e Forma:SolidPeso molecular:551.53Androgen receptor ligand 1
CAS:<p>Androgen receptorligand 1 is a ligand for the androgen receptor (AR). It interacts with the CRBN E3 ligase via a linker to form an AR-PROTAC degrader. This compound is useful in prostate cancer research.</p>Fórmula:C19H16F4N2OCor e Forma:SolidPeso molecular:364.34A4B17
<p>A4B17 is an inhibitor of androgen receptor N-terminal with potential for androgen-responsive prostate cancer treatment.</p>Fórmula:C14H7F4NSCor e Forma:SolidPeso molecular:297.27
